Format

Send to

Choose Destination
J Clin Oncol. 1992 Apr;10(4):587-90.

Curability of solitary bone plasmacytoma.

Author information

1
University of Texas M.D. Anderson Cancer Center, Houston 77030.

Abstract

PURPOSE:

The effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP).

PATIENTS AND METHODS:

Forty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67% of patients showed a myeloma protein, and uninvolved immunoglobulins (Igs) were preserved in 93% of patients.

RESULTS:

Permanent control of presenting disease was achieved in all but two patients, but 46% of patients developed multiple myeloma. When it occurred, progression of myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma protein disappeared in nine patients (30%) whose disease has not yet recurred. The median survival for all patients was 13 years and the myeloma-specific survival fraction at 10 years was 53%.

CONCLUSION:

In patients with an SBP, the disappearance of myeloma protein with involved-field radiotherapy predicted long-term disease-free survival and possible cure. Nonsecretory disease and persistent myeloma protein after treatment were adverse prognostic factors for which adjuvant therapy with interferon alfa should be considered.

PMID:
1548521
DOI:
10.1200/JCO.1992.10.4.587
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center